论文部分内容阅读
目的：研究ｐｏ洛伐他汀胶囊与美降之片后，洛伐他汀在血浆中的药动学与相对生物利用度。方法：采用反相高效液相色谱法测定１０名志愿受试者单剂量ｐｏ１００ｍｇ洛伐他汀胶囊与美降之片后，洛伐他汀血药浓度变化情况，计算药动学参数与相对生物利用度，并以配对ｔ检验与双单侧ｔ检验进行统计分析。结果：两制剂的ＡＵＣ分别是：（３３４．８±４０．９）ｎｇ·ｈ·ｍｌ－１与（３４３．２±５４．２）ｎｇ·ｈ·ｍｌ－１，ｔｍａｘ分别为：（２．５±０．４）ｈ与（２．５±０．３）ｈ，ｃｍａｘ分别是：（４５．６±４．８）ｎｇ·ｍｌ－１与（４３．３±５．９）ｎｇ·ｍｌ－１。配对ｔ检验与双单侧ｔ检验结果表明：ＡＵＣ，ｃｍａｘ，ｔｍａｘ均无显著性差异（Ｐ＞０．０５）。结论：洛伐他汀胶囊与美降之片为生物等效制剂；洛伐他汀胶囊的相对生物利用度为（９８．４５±１０．１８）％。
OBJECTIVE: To study the pharmacokinetics and relative bioavailability of lovastatin in plasma after po lovastatin capsules and melphalan tablets. Methods: The change of lovastatin plasma concentration after single-dose po100mg lovastatin capsules and beauty tablets were measured in 10 volunteers by RP-HPLC. The pharmacokinetic parameters and relative bioavailability , And paired t-test and double unilateral t test for statistical analysis. Results: The AUC of the two preparations were (334.8 ± 40.9) ng · h · ml-1 and (343.2 ± 54.2) ng · h · ml-1, respectively. 5 ± 0.4) h and (2.5 ± 0.3) h, cmax were (45.6 ± 4.8) ng · ml-1 and (43.3 ± 5.9) ng · ml -1. Paired t-test and double-sided t-test showed that there was no significant difference in AUC, cmax, tmax (P> 0.05). Conclusion: The lovastatin capsules and the beauty tablets are bioequivalent. The relative bioavailability of lovastatin capsules is (98.45 ± 10.18)%.